Cardiogen

AEDR tetrapeptide research reference · Khavinson-lineage cardiac literature

Lot-specific chromatographic purity and quantitative peptide content; confirm both on the released-lot COA · target, verify batch COACAS 857267-11-9RUO

Research statusLimited preclinical evidence from a concentrated research lineage; laboratory Research Use Only

Supplied formLinear tetrapeptide; H-Ala-Glu-Asp-Arg-OH (AEDR)

Lead time14–21 days

Cardiogen — Lot-specific lyophilized research peptide; confirm colour and cake condition on the released-lot COA

Cardiogen — Lot-specific lyophilized research peptide; confirm colour and cake condition on the released-lot COA · Representative packaging image · verify the ordered lot

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research applications include AEDR identity and sequence qualification, myocardial or fibroblast cell models, cytoskeletal/nuclear-matrix readouts and replication of peptide-histone interaction findings
Reported tumour-model findings are a separate preclinical context and do not establish cardiovascular or anticancer efficacy.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 857267-11-9
Formula: C₁₈H₃₁N₇O₉
Molecular weight: Approximately 489.5 Da
Appearance: Lot-specific lyophilized research peptide; confirm colour and cake condition on the released-lot COA
Purity: Lot-specific chromatographic purity and quantitative peptide content; confirm both on the released-lot COA · target, verify batch COA
Storage: Follow the released-lot COA, SDS and formulation-specific stability statement. Temperature, light protection, shipping range, container and any prepared-solution hold time require evidence for the exact AEDR form, matrix and concentration.
MOQ: On request
Lead time: 14–21 days

PubChem CID 11583989

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about Cardiogen

Cardiogen is specified as the linear tetrapeptide H-Ala-Glu-Asp-Arg-OH, abbreviated AEDR from its four residues. PubChem CID 11583989 independently supports that full residue sequence, formula C₁₈H₃₁N₇O₉ and molecular weight 489.5 Da. Research from the Khavinson network includes a rat myocardial-explant study, a mouse-embryonic-fibroblast study, a senescent-rat M-1 sarcoma model and a wheat-histone interaction study. No sequence-confirmed human clinical trial or pharmacokinetic programme was identified. CAS 857267-11-9 is consistently mapped by several supplier catalogues but is not displayed in the accessible PubChem synonyms, so sequence-resolved batch evidence remains primary.

Sequence and identity qualification; myocardial-tissue, fibroblast, cytoskeletal/nuclear-matrix and histone-interaction assays; and carefully controlled preclinical replication
These are research applications, not clinical indications.

Mechanism context

The question the literature is testing

PMID 20210190 reports that 10⁻¹² M Cardiogen increased the outgrowth zone in organotypic myocardial explants from 3- and 24-month-old rats and was associated with lower p53 expression; this was an ex-vivo tissue-culture experiment, not an in-vivo efficacy or dose study. PMID 22977870 separately reports 2-5-fold increases in cytoskeletal proteins and 2-3-fold increases in lamin A/C in cultured mouse embryonic fibroblasts; its claim that these changes explain cardioprotection is the authors' interpretation. PMID 23581987 reports in-vitro binding of AEDR and five other short peptides to FITC-labelled wheat histones and histone-deoxyribooligonucleotide complexes. No direct causal chain from those findings to human cardiac outcomes or tissue targeting has been established.

Evidence map

Research routes and exposure context

Evidence tierMixed evidence context

Research areaKhavinson bioregulators

Routes reported in sources

No administration route applies

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Not for human or veterinary use
Preclinical proliferation, apoptosis and tumour-model observations do not establish human safety or a contraindication framework
The M-1 sarcoma study cannot be generalized to human cancer or other tumour types
Follow the SDS and institutional controls; chemical purity does not establish sterility or injectable suitability.

Interactions reported in the literature

No controlled combination or drug-interaction studies were identified
Pairings with Vesugen, BPC-157, TB-500 or other Khavinson peptides are vendor/community hypotheses, not validated compatibility or safety guidance.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

Cardiogen factory batch COAs

Cardiogen 20 mg Factory batch COA protected preview

Cardiogen20 mg · WHJLP-CAR20-260518-C

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

Require exact AEDR sequence and termini, supplied form/counterion, theoretical and observed high-resolution intact mass, sequence evidence, stability-indicating HPLC purity and impurity profile, quantitative peptide content, water/counterion/residuals and lot-specific stability
Sterility, bacterial endotoxin and bioburden are independent attributes
A white appearance, clear solution or “>97%” area result alone is insufficient.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

CARD-20MG20 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Follow the released-lot COA, SDS and formulation-specific stability statement. Temperature, light protection, shipping range, container and any prepared-solution hold time require evidence for the exact AEDR form, matrix and concentration.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Identity: PubChem CID 11583989. Myocardial explant and p53 study: PMID 20210190. Cytoskeletal/nuclear-matrix study: PMID 22977870. Senescent-rat M-1 sarcoma model: PMID 20396706. Wheat-histone-complex interaction: PMID 23581987. A 2023 Cells review in PMC9818427 provides same-network secondary synthesis. These records support a limited preclinical research context, not human dosing, efficacy or safety.

01
Tetrapeptide H-Ala-Glu-Asp-Arg-OH stimulates expression of cytoskeletal and nuclear matrix proteins
Bulletin of Experimental Biology and Medicine · 2012 · peer-reviewed original research
Open source
02
The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats
Advances in Gerontology · 2009 · peer-reviewed original research (Russian article with English abstract)
Open source
03
Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats
Bulletin of Experimental Biology and Medicine · 2009 · peer-reviewed original research
Open source
04
Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides
Biochemistry (Moscow) · 2013 · peer-reviewed original in-vitro research
Open source
05
Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation
Cells (MDPI) · 2023 · peer-reviewed review article
Open source
06
Peptide substance restoring myocardium function (US Patent 7,662,789 B2)
United States Patent and Trademark Office / Google Patents · 2010 · regulatory document (granted patent)
Open source
07
Peptide compound recovering function of myocardium (RU Patent 2255756 C1)
Russian Federal Service for Intellectual Property / Google Patents · 2005 · regulatory document (granted patent)
Open source
08
Peptide medicines: past, present, future
Clinical Medicine (Russian Journal) / Klinicheskaya Meditsina · 2020 · peer-reviewed review article (author overview)
Open source

Product FAQ

Questions buyers ask about Cardiogen

What is established about Cardiogen identity?+

PubChem CID 11583989 supports the full H-Ala-Glu-Asp-Arg-OH residue sequence, AEDR residue abbreviation, formula C₁₈H₃₁N₇O₉ and molecular weight approximately 489.5 Da. The quote and COA should also specify termini, salt/counterion, theoretical and observed intact mass, sequence evidence and quantitative peptide content. CAS 857267-11-9 is a secondary catalogue mapping and should not replace those controls.

How strong is the cardiac evidence?+

Published work includes a rat myocardial-explant study reporting proliferation and lower p53 expression, a mouse-embryonic-fibroblast study reporting cytoskeletal/nuclear-matrix protein changes, and a separate senescent-rat M-1 sarcoma model. Another in-vitro paper reports AEDR interaction with wheat histones. These findings come from a concentrated research lineage and do not establish a sequence-confirmed human cardiovascular benefit, pharmacokinetic profile or clinical safety; histone binding has not been causally linked to cardioprotection.

What should a Cardiogen lot-release package contain?+

Require exact N-to-C AEDR sequence and termini, salt/counterion and theoretical mass; high-resolution intact mass and sequence evidence; stability-indicating HPLC method and impurity profile; quantitative peptide content; water, counterion and relevant residuals; and lot-specific storage evidence. Sterility, bacterial endotoxin and bioburden are separate tests and cannot be inferred from appearance or chemical purity.

Cardiogen

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about Cardiogen

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

Cardiogen factory batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

Tetrapeptide H-Ala-Glu-Asp-Arg-OH stimulates expression of cytoskeletal and nuclear matrix proteins

The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats

Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats

Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides

Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation

Peptide substance restoring myocardium function (US Patent 7,662,789 B2)

Peptide compound recovering function of myocardium (RU Patent 2255756 C1)

Peptide medicines: past, present, future

Questions buyers ask about Cardiogen

Compare adjacent molecules and documentation needs.

Bronchogen

Cortagen

Vesugen

Cartalax